Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

BACKGROUND: Evidence concerning the importance of glucose lowering in the prevention of cardiovascular (CV) outcomes remains controversial. Given the multi-faceted pathogenesis of atherosclerosis in diabetes, it is likely that any intervention to mitigate this risk must address CV risk factors beyon...

Descripción completa

Detalles Bibliográficos
Autores principales: Zinman, Bernard, Inzucchi, Silvio E, Lachin, John M, Wanner, Christoph, Ferrari, Roberto, Fitchett, David, Bluhmki, Erich, Hantel, Stefan, Kempthorne-Rawson, Joan, Newman, Jennifer, Johansen, Odd Erik, Woerle, Hans-Juergen, Broedl, Uli C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072621/
https://www.ncbi.nlm.nih.gov/pubmed/24943000
http://dx.doi.org/10.1186/1475-2840-13-102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072621/
https://www.ncbi.nlm.nih.gov/pubmed/24943000
http://dx.doi.org/10.1186/1475-2840-13-102

Ejemplares similares